|
|
 |
|
Viewing report
|
|
|
|
Biopharma Quarter: Key Trends and Events of the First Quarter of 2009
Decision Resources, Inc., June 2009, Pages: 47
No Bear Stearns, no Lehman Brothers, no Chrysler, no humiliating hat-in-hand audiences with Congress. The biopharma industry has not seen one of its leaders tumble in the way that the financial and automotive industries have. Certainly, though, many smaller players are succumbing in the international economic meltdown; major players are making moves that are critical to their survival; and the possibility of a federal bailout of the biotech industry has been raised. Clearly, the state of the economy is hastening change in the industry, which will confront a narrowed playing fi eld, greater cost-consciousness, and opportunities to innovate in terms of technologies and business models.
Get the Answers You Need to Shape Your Strategy
- The first quarter brought the return of the mega-merger. What do these mammoth deals signal for the Big Pharma/Big Biotech participants? What do they say about the industry in general?
- Healthcare reform debates continue in the United States. What is the state of the coalition exploring change? What does the financial stimulus package mean for healthcare?
- Small biotechs are suffering given the current economic condition. What is the outlook for this sector? How has the investment environment been affected? Where are the opportunities?
- Many companies are targeting biosimilar development, recognizing that payers will embrace these alternatives. How is U.S. regulatory guidance shaping up? What companies are pursuing biosimilar approvals? What is the outlook for Teva, which has announced that it will pursue a biosimilar BLA?
Scope
- Events: guidance and approvals involving transgenic animals; biotech industry financial and investment trends, challenges, opportunities, and outlook; U.S. stimulus package funding in the healthcare arena.
- Dealmaking: deal volume, deal type, deal value, deal focus, most active companies, therapeutic area focus, biologics focus.
- Generics: Actavis and Ratiopharm up for sale; layoffs announced at key generics companies; the push for biosimilars.
- Strategy: return of the mega-merger; pending healthcare reform in the United States; Big Pharma’s philanthropic ventures in developing countries.
- Expert commentary: “Biotech Investment Trends: The Quest for Capital,” by Decision Resources senior analyst Barbara M. Bolten, M.S., M.B.A.
Customers who bought this item also bought
Mega-Mergers: Executing Change in the Pharma Industry
State of the Pharmaceutical Industry, 2010 - Critical Role of Midsize Pharma
Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008
Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer
Biopharma Quarter: Key Trends and Events of the Second Quarter of 2009
Pharmaceutical Industry Dynamics 2010: Licensing Opportunities: Rheumatology
Value-Added Pharma: How to Accomplish the Impossible
Opportunities for Monoclonal Antibodies: Where Companies Are Spending Their Antibody Dollars
Biosimilar Opportunities: Pipelines and Companies
Biosimilars - Global Strategic Business Report
|
|
|
|
